A5037654589- Diabetes Treatment and Management
- Diabetes Management and Research
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes and associated disorders
- Metabolism, Diabetes, and Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic function and diabetes
- Pharmaceutical studies and practices
- Chronic Disease Management Strategies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Blood Pressure and Hypertension Studies
- Diabetes Management and Education
- Pharmaceutical Economics and Policy
- Pharmacology and Obesity Treatment
- Cardiovascular Function and Risk Factors
- Chronic Kidney Disease and Diabetes
- Medication Adherence and Compliance
- Pharmaceutical Practices and Patient Outcomes
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Hepatitis C virus research
- Statistical Methods in Clinical Trials
- Neuroendocrine Tumor Research Advances
- Antiplatelet Therapy and Cardiovascular Diseases
- Neuroblastoma Research and Treatments
Universitas Patria Artha
2016
University of Tennessee Health Science Center
2005-2009
Durham University
2009
Health Economics and Outcomes Research (United Kingdom)
2008
IQVIA (United States)
2007
Center for Outcomes Research and Clinical Epidemiology
2004-2006
Cardiff University
2005
University Hospital of Wales
2005
Kantonsspital St. Gallen
2005
IQVIA (United Kingdom)
2004
We have developed an Internet-based, interactive computer model to determine the long-term health outcomes and economic consequences of implementing different treatment policies or interventions in type 1 2 diabetes mellitus. The projects for populations, taking into account baseline cohort characteristics past history complications, current future management concomitant medications, screening strategies changes physiological parameters over time. development life expectancy,...
To assess the cost-effectiveness of intensive versus conventional therapy for 8 years as applied in Steno-2 study patients with type 2 diabetes and microalbuminuria.
People with chronic infectious diseases such as hepatitis B can face stigma, which influence everyday life well willingness to engage medical professionals or disclose disease status. A systematic literature review was performed characterize the level and type of stigma experienced by people infected virus (HBV) identify instruments used measure it.A using PubMed, Embase Cochrane Library databases studies describing HBV-related stigma. For inclusion, articles were required be published in...
Over 4 million patients suffer nosocomial infections annually in the European Union. This study aimed to estimate healthcare burden associated with healthcare-associated (HAIs) following surgery France, and explore potential impact of infection control strategies interventions on clinical economic disease. Data frequency HAIs were gathered from 2010 Programme de Médicalisation des Systèmes d'Information (PMSI), cost data taken 2009 Echelle Nationale Coûts à Méthodologie Commune (ENCC). It...
Abstract Objectives The aim of this study was to project the long‐term costs and outcomes continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) in patients Type 1 diabetes UK. Methods CORE Diabetes Model is a peer‐reviewed, validated model which employs standard Markov/Monte Carlo simulation techniques describe incidence progression diabetes‐related complications. It used simulate disease cohort baseline characteristics taken from published UK studies...
Objective. To evaluate the cost‐effectiveness of Project Dulce, a culturally specific diabetes case management and self‐management training program, in four cohorts defined by insurance status. Data Sources/Study Setting. Clinical cost data on 3,893 persons with participating Dulce were used as inputs into simulation model. Study Design. The Center for Outcomes Research Diabetes Model, published, peer‐reviewed validated model diabetes, was to life expectancy, quality‐adjusted expectancy...
Real-world evidence has demonstrated improved glycemic control and insulin management following introduction of smart pens in a Swedish type 1 diabetes (T1D) population. To understand the implications for healthcare costs expected health outcomes, this analysis evaluated long-term cost-effectiveness introducing to standard-of-care T1D treatment (standard care) from societal perspective. Clinical outcomes (in 2018 krona, SEK) were projected over patients' lifetimes using IQVIA CORE Diabetes...
Background and aims: Effective glycemic control is the cornerstone of successful type 2 diabetes management. However, many patients fail to reach targets, therapeutic inertia (failure intensify therapy address poor in a timely manner) has been widely reported. The aim present study was evaluate economic burden associated with diabetes-related complications due for UK.Methods: A validated long-term model (IQVIA CORE Diabetes Model) used project cost outcomes UK population diabetes, based on...
The PIONEER trial programme showed that, after 52 weeks, the novel oral glucagon-like peptide-1 (GLP-1) analogue semaglutide 14 mg was associated with significantly greater reductions in glycated haemoglobin (HbA1c) versus a sodium-glucose cotransporter-2 inhibitor (empagliflozin 25 mg), dipeptidyl peptidase-4 (sitagliptin 100 mg) and an injectable GLP-1 (liraglutide 1.8 mg). aim of present analysis to assess long-term cost-effectiveness each these comparators UK setting.Analyses were...
Therapeutic inertia refers to the failure initiate or intensify treatment in a timely manner and is widespread type 2 diabetes (T2D) despite well-established importance of maintaining good glycemic control. The aim this analysis was quantify clinical economic burden associated with poor control due therapeutic patients T2D USA. IQVIA CORE Diabetes Model used simulate life expectancy, costs diabetes-related complications, lost workplace productivity US patients. Baseline glycated hemoglobin...
Recent data have shown that type 2 diabetes patients in the UK delay initiating insulin on average for over 11 years after first being prescribed an oral medication. Using a published computer simulation model of we used UK-specific to estimate clinical consequences immediately versus delaying initiation periods line with estimates.In base case scenario simulated patients, characteristics based data, were modelled as either or 8 years. Clinical outcomes terms both life expectancy and...
To investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with Type 2 diabetes uncontrolled first-line metformin.Data were sourced from a clinical trial comparing glimepiride, both combination metformin, and sitagliptin, metformin. Only subgroup whom was added monotherapy included cost-utility analysis. The CORE Diabetes Model used simulate outcomes costs 1.2 1.8 mg over patients' lifetimes. Treatment effects taken directly trials....
Objectives: The aim of this study was to evaluate the long-term clinical and economic outcomes associated with exenatide or insulin glargine, added oral therapy in individuals type 2 diabetes inadequately controlled combination agents UK setting.Methods: A published validated computer simulation model used project complications, life expectancy, quality-adjusted expectancy direct medical costs. Probabilities diabetes-related complications were derived from sources. Treatment effects patient...
Effective glycemic control can reduce the risk of serious micro- and macrovascular complications in type 2 diabetes. However, many patients fail to reach targets due partly low efficacy adverse effects treatment such as hypoglycemia or weight gain.To evaluate short-term cost-effectiveness liraglutide versus sitagliptin, terms cost per patient reaching a glycated hemoglobin (HbA1c) target with no gain after 52 weeks, based on recently published trial. Data were taken from 52-week randomized,...
Continuous subcutaneous insulin infusion (CSII) is an important treatment option for type 1 diabetes patients unable to achieve adequate glycemic control with multiple daily injections (MDI). Combining CSII continuous glucose monitoring (CGM) in sensor-augmented pump therapy (SAP) a low glucose-suspend (LGS) feature may further improve and reduce the frequency of hypoglycemia. A cost-effectiveness analysis SAP + LGS vs. plus self-monitoring blood (SMBG) was performed determine health...